Key result
Initiating rivaroxaban within 14 days of mild-moderate cardioembolic stroke or TIA was safe, with 0% of patients developing symptomatic hemorrhagic transformation at day 7.
Why the study?
Does early initiation of rivaroxaban (≤14 days) safely prevent symptomatic hemorrhagic transformation in patients with atrial fibrillation and mild-moderate cardioembolic stroke or TIA?
Cohort (n=60)
Open-label
Does early initiation of rivaroxaban (≤14 days) safely prevent symptomatic hemorrhagic transformation in patients with atrial fibrillation and mild-moderate cardioembolic stroke or TIA?
Early initiation of rivaroxaban within 14 days of mild-to-moderate cardioembolic stroke or TIA appears safe and does not result in symptomatic hemorrhagic transformation.
Authors
No takes yet. Share an insight, caveat, or question.
May support early rivaroxaban after mild-moderate cardioembolic events; hypothesis-generating and requires randomized confirmation before practice change.
Gioia et al. (2016) conducted a cohort in Cardioembolic stroke or transient ischemic attack with atrial fibrillation (n=60). Rivaroxaban was evaluated on Symptomatic hemorrhagic transformation at day 7. Initiating rivaroxaban within 14 days of mild-moderate cardioembolic stroke or TIA was safe, with 0% of patients developing symptomatic hemorrhagic transformation at day 7.